Association Study of Fat-mass and Obesity-associated Gene and Body Mass Index in Japanese Patients with Schizophrenia and Healthy Subjects
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objective: Fat-mass and obesity-associated (FTO) gene is known to be involved in the pathophysiology of obesity and a single-nucleotide polymorphism (SNP) rs9939609 of FTO gene is repeatedly confirmed to be associated with body mass index (BMI) and obesity. The aim of this study is to elucidate effects of FTO gene polymorphism on BMI in Japanese patients with schizophrenia and healthy subjects. Methods: Three hundred fifty one patients with schizophrenia and 342 age- and sex- matched healthy subjects participated in the study. Information on BMI and antipsychotic medication was also collected from patients and healthy subjects. Genotype of the FTO SNP rs9939609 was determined by TaqMan SNP Genotyping Assays. Results: There was no significant difference in BMI between patients and healthy subjects. No significant difference in BMI was observed among any medications. We observed no significant difference in rs9939609 allele frequencies between patients and healthy subjects. There was a significant difference in BMI between healthy subjects with risk (AA or TA) genotypes and those with TT genotype. We also observed a significant positive correlation between the number of risk allele (A allele) and BMI in healthy subjects. Conclusion: Our study suggested that FTO rs9939609 polymorphism might have some impacts on the BMI in healthy subjects,but might not have same impacts on the BMI of patients with schizophrenia.
Abstract
Objective: Fat-mass and obesity-associated (FTO) gene is known to be involved in the pathophysiology of obesity and a single-nucleotide polymorphism (SNP) rs9939609 of FTO gene is repeatedly confirmed to be associated with body mass index (BMI) and obesity. The aim of this study is to elucidate effects of FTO gene polymorphism on BMI in Japanese patients with schizophrenia and healthy subjects. Methods: Three hundred fifty one patients with schizophrenia and 342 age- and sex- matched healthy subjects participated in the study. Information on BMI and antipsychotic medication was also collected from patients and healthy subjects. Genotype of the FTO SNP rs9939609 was determined by TaqMan SNP Genotyping Assays. Results: There was no significant difference in BMI between patients and healthy subjects. No significant difference in BMI was observed among any medications. We observed no significant difference in rs9939609 allele frequencies between patients and healthy subjects. There was a significant difference in BMI between healthy subjects with risk (AA or TA) genotypes and those with TT genotype. We also observed a significant positive correlation between the number of risk allele (A allele) and BMI in healthy subjects. Conclusion: Our study suggested that FTO rs9939609 polymorphism might have some impacts on the BMI in healthy subjects,but might not have same impacts on the BMI of patients with schizophrenia.
참고문헌 (21)
- Casey DE, "Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia", J Clin Psychiatry, 65(Suppl 7), pp.4~18 (2004)
- De Luca V, "Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis", Int J Neuropsychopharmacol, 10, pp.697~704 (2007)
- Gunes A, "Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine", J Clin Psychopharmacol, 29, pp.65~68 (2009)
- Sicard MN, "Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and metaanalysis", Pharmacogenomics, 11, pp.1561~1571 (2010)
- Hong CJ, "Genetic variant of the histamine-1 receptor (glu349asp) and body weight change during clozapine treatment", Psychiatr Genet, 12, pp.169~171 (2002)
- Hong CJ, "Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment", Pharmacogenet Genomics, 20, pp.359~366 (2010)
- Lencz T, "DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia", Pharmacogenet Genomics, 20, pp.569~572 (2010)
- Popp J, "DRD4 48 bp VNTR but not 5-HT 2C Cys23Ser receptor polymorphism is related to antipsychotic-induced weight gain", Pharmacogenomics J, 9, pp.71~77 (2009)
- Park YM, "Weight gain associated with the alpha2a-adrenergic receptor-1,291 C", G polymorphism and olanzapine treatment, 2006, pp.141B, 394~397
- Ujike H, "Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study", J Clin Psychiatry, 69, pp.1416~1422 (2008)
- Dina C, "Variation in FTO contributes to childhood obesity and severe adult obesity", Nat Genet, 39, pp.724~726 (2007)
- Frayling TM, "A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity", Science, 316, pp.889~894 (2007)
- Ikeda M, "Genome-wide association study of schizophrenia in a Japanese population", Biol Psychiatry, 69, pp.472~478 (2011)
- Yamada K, "Genome-wide association study of schizophrenia in Japanese population", PLoS One, 6, pp.e20468~ (2011)
- Tabara Y, "Prognostic significance of FTO genotype in the development of obesity in Japanese: the J-SHIPP study", Int J Obes, 33, pp.1243~1248 (2009)
- Karasawa S, "Association of the common fat mass and obesity associated (FTO) gene polymorphism with obesity in a Japanese population", Endocr J, 57, pp.293~301 (2010)
- Fredriksson R, "The obesity gene, FTO, is of ancient origin, up-regulated during food deprivation and expressed in neurons of feeding-related nuclei of the brain", Endocrinology, 149, pp.2062~2071 (2008)
- Cecil JE, "An obesity-associated FTO gene variant and increased energy intake in children", N Engl J Med, 359, pp.2558~2566 (2008)
- Perez-Iglesias R, "Effect of FTO, SH2B1, LEP, and LEPR polymorphisms on weight gain associated with antipsychotic treatment", J Clin Psychopharmacol, 30, pp.661~666 (2010)
- Johnson L, "Dietary energy density affects fat mass in early adolescence and is not modified by FTO variants", PLoS One, 4, pp.e4594~ (2009)
- Vimaleswaran KS, "Physical activity attenuates the body mass index-increasing influence of genetic variation in the FTO gene", Am J Clin Nutr, 90, pp.425~428 (2009)